BioMarin acquires experimental drug for rare bone disorder in $275M deal

BioMarin acquires experimental drug for rare bone disorder in $275M deal →

The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.